Cyclacel pharmaceuticals reports fourth quarter and full year 2023 financial results and provides business update

– on track to start oral fadraciclib phase 2 proof of concept in 1h 2024 – –  expect to report final data from fadraciclib 065-101 dose escalation – – oral plogosertib preclinical data support precision medicine strategy in arid1a- and smarca-mutated cancers  – – management to host conference call at 4:30 pm et today – berkeley heights, n.j., march 19, 2024 (globe newswire) -- cyclacel pharmaceuticals, inc. (nasdaq: cycc, nasdaq: cyccp; "cyclacel" or the "company"), a biopharmaceutical company developing innovative medicines based on cancer cell biology, today announced fourth quarter and full year 2023 financial results and provided a business update.
CYCC Ratings Summary
CYCC Quant Ranking